BPG is committed to discovery and dissemination of knowledge
Featured Articles
12/26/2018 3:20:09 AM | Browse: 884 | Download: 2191
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 42267
Country South Korea
ISSN 1948-5204 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Clinical Trials Study
Article Title Multicenter phase Ⅱ trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
Manuscript Source Unsolicited Manuscript
All Author List Moon Jae Chung, Huapyong Kang, Ho Gak Kim, Jong Jin Hyun, Jun Kyu Lee, Kwang Hyuck Lee, Myung Hwan Noh, Dae Hwan Kang, Sang Hyub Lee and Seungmin Bang
Funding Agency and Grant Number
Corresponding Author Seungmin Bang, MD, PhD, Professor, Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, South Korea. bang7028@yuhs.ac
Key Words Pancreatic cancer; FOLFIRINOX; Clinical Trial, Phase Ⅱ; Chemotherapy; Gemcitabine refractory
Core Tip For gemcitabine (GEM)-refractory unresectable pancreatic cancer (PC), there are limited options of second-line chemotherapy regimen. To find new treatment option for GEM-refractory unresectable PC, we conducted a multicenter phase Ⅱ trial, which evaluated the efficacy and safety of uniquely modified FOLFIRINOX with reduced irinotecan and oxaliplatin. In our results, FOLFIRINOX with reduced irinotecan and oxaliplatin showed acceptable toxicity and promising efficacy. With careful observation of treatment-related hematologic toxicities, this chemotherapy regimen is a promising option for patients with GEM-refractory PC after first-line treatment failure.
Publish Date 2018-12-14 10:51
Citation Chung MJ, Kang H, Kim HG, Hyun JJ, Lee JK, Lee KH, Noh MH, Kang DH, Lee SH, Bang S, Pancreatobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer. Multicenter phase Ⅱ trial of modified FOLFIRINOX in gemcitabin-refractory pancreatic cancer. World J Gastrointest Oncol 2018; 10(12): 505-515
URL https://www.wjgnet.com/1948-5204/full/v10/i12/505.htm
DOI https://dx.doi.org/10.4251/wjgo.v10.i12.505
Full Article (PDF) WJGO-10-505.pdf
Full Article (Word) WJGO-10-505.docx